Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imgatuzumab

Next Previous
X
Search
Drug Profile

Imgatuzumab

Alternative Names: GA-201; R7160; RG-7160; RO-5083945

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GLYCART Biotechnology
  • Developer PegaOne; Roche
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer

Most Recent Events

  • 17 Aug 2022 PegaOne withdraws a phase II trial for Squamous cell cancer (Late-stage disease) in Australia (IV) (NCT04985825)
  • 30 Mar 2022 Discontinued - Phase-II for Squamous cell cancer (Late-stage disease) in Australia, prior to march 2022 (IV)
  • 01 Nov 2016 Roche withdraws a phase I trial in Non-small cell lung cancer (Late-stage disease, metastatic disease, combination therapy, first-line therapy) before enrollment in USA (NCT01702714) due to project team decision

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top